20:00 , Apr 23, 2019 |  BC Extra  |  Company News

Pilot program for GSK's malaria vaccine starts in Malawi

WHO launched a planned pilot program of GSK's malaria vaccine RTS,S in Malawi on Tuesday with the goal of informing the organization's policy recommendations for broader use of the vaccine. The organization will also roll...
20:04 , Apr 18, 2019 |  BC Innovations  |  Translation in Brief

Agenus scales the AI ALPS

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data....
21:19 , Mar 22, 2019 |  BC Extra  |  Company News

Management tracks: Mirum, Novocure

Mirum said Mike Grey has stepped down as CEO but will remain executive chairman. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) promoted President Chris Peetz to CEO. Peetz is also a director. Mirum launched in 2018...
23:23 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Diabetes Mouse studies suggest agonizing GITR could help treat insulin resistance. In genetic and high-fat diet-induced mouse models of insulin resistance, a GITR agonist mAb increased glucose tolerance and insulin sensitivity and decreased fasting...
18:53 , Feb 7, 2019 |  BC Week In Review  |  Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
01:05 , Feb 5, 2019 |  BC Extra  |  Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
19:52 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) said Jan. 29 that is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is...
19:21 , Jan 29, 2019 |  BC Extra  |  Financial News

Agenus to sell blockchain tokens to fund PD-1 development

Agenus Inc. (NASDAQ:AGEN) is seeking to raise up to $100 million via the sale of blockchain-powered tokens tied to clinical anti-PD-1 mAb AGEN2034. The company said the asset-backed digital security is the first of its...
19:25 , Dec 21, 2018 |  BC Week In Review  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). Gilead received exclusive, worldwide rights to AGEN1423, options to bispecific antibody AGEN1223 and...
00:06 , Dec 21, 2018 |  BC Extra  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). The deal, Gilead's second of the week, will also extend Agenus’ cash reserves....